TY - JOUR
T1 - Tumor Immune Microenvironment of Brain Metastases
T2 - Toward Unlocking Antitumor Immunity
AU - Strickland, Matthew R.
AU - Alvarez-Breckenridge, Christopher
AU - Gainor, Justin F.
AU - Brastianos, Priscilla K.
N1 - Publisher Copyright:
© 2022 American Association for Cancer Research.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Brain metastasis (BrM) is a devastating complication of solid tumors associated with poor outcomes. Immune-checkpoint inhibitors (ICI) have revolutionized the treatment of cancer, but determinants of response are incompletely understood. Given the rising incidence of BrM, improved understanding of immunobiologic principles unique to the central nervous system (CNS) and dissection of those that govern the activity of ICIs are paramount toward unlocking BrM-specific antitumor immunity. In this review, we seek to discuss the current clinical landscape of ICI activity in the CNS and CNS immunobiology, and we focus, in particular, on the role of glial cells in the CNS immune response to BrM. Significance: There is an urgent need to improve patient selection for and clinical activity of ICIs in patients with cancer with concomitant BrM. Increased understanding of the unique immunobiologic principles that govern response to ICIs in the CNS is critical toward identifying targets in the tumor microenvironment that may potentiate antitumor immunity.
AB - Brain metastasis (BrM) is a devastating complication of solid tumors associated with poor outcomes. Immune-checkpoint inhibitors (ICI) have revolutionized the treatment of cancer, but determinants of response are incompletely understood. Given the rising incidence of BrM, improved understanding of immunobiologic principles unique to the central nervous system (CNS) and dissection of those that govern the activity of ICIs are paramount toward unlocking BrM-specific antitumor immunity. In this review, we seek to discuss the current clinical landscape of ICI activity in the CNS and CNS immunobiology, and we focus, in particular, on the role of glial cells in the CNS immune response to BrM. Significance: There is an urgent need to improve patient selection for and clinical activity of ICIs in patients with cancer with concomitant BrM. Increased understanding of the unique immunobiologic principles that govern response to ICIs in the CNS is critical toward identifying targets in the tumor microenvironment that may potentiate antitumor immunity.
UR - http://www.scopus.com/inward/record.url?scp=85129781100&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129781100&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-21-0976
DO - 10.1158/2159-8290.CD-21-0976
M3 - Article
C2 - 35394521
AN - SCOPUS:85129781100
SN - 2159-8274
VL - 12
SP - 1199
EP - 1216
JO - Cancer discovery
JF - Cancer discovery
IS - 5
ER -